EFGCP Gives Priority to ‘Two Ends of Life’
The two ends of life can be viewed separately, but they have many common elements like frailty or vulnerability, and these shared aspects mean that geriatric and pediatric drug development should be viewed together, according to the European Forum for GCP (EFGCP).
This philosophy has inspired the Children’s Medicines and Geriatric Medicines Working Parties of the EFGCP to organize a joint meeting, called “Multi-Stakeholder Workshop on Facilitating Medicines Development for Youth and the ‘Young at Heart’: Learning for Intergenerational Strategies,” to be held in London on 21 November.
“The development of drugs is evolving and much effort is being put into understanding in special populations like children and older people,” noted a statement from the organizers. “The agenda reflects important topics like the special ethical considerations that can affect the informed consent process, evaluation of the safety parameters which is dependent of the adequate reporting of adverse events, and interpretation of the adverse drug reactions and proper use of modelling of simulation to bring value to the drug development process.”
The objective is to share challenges, to detect possible synergies, and to learn from each other to improve and facilitate high quality ethical clinical research and drug development for these populations across Europe, they added.
For more details about the event, click here.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
